+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Onychomycosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)- Product Image
Onychomycosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)- Product Image
New

Onychomycosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 260 Pages
  • March 2025
  • Region: Global
  • Fairfield Market Research
  • ID: 6060232
Description Jump to:
The global onychomycosis treatment market is projected to grow significantly in the coming years, fueled by increasing awareness, advancements in diagnostic technology, and the growing prevalence of fungal infections due to aging populations and lifestyle factors. According to recent analysis, the market is anticipated to surge from US$58.2 billion in 2025 to US$99.1 billion by 2032, registering a CAGR of 8% during the forecast period.

Market Insights

Recent innovations in diagnostic technologies, including optical coherence tomography, confocal microscopy, and polymerase chain reaction (PCR), have improved the early detection and precise identification of fungal pathogens. These developments have led to enhanced treatment targeting and higher therapeutic efficacy. Laser treatments, especially Nd: YAG lasers, have emerged as effective, non-invasive alternatives to traditional therapies. Meanwhile, advancements in nanotechnology and liposomal formulations are boosting topical drug penetration and reducing systemic side effects.

Moreover, digital health tools such as telemedicine and 3D printing are reshaping treatment approaches. Virtual consultations, medication reminders, and patient education apps enhance treatment adherence, while 3D printing allows the customization of drug formulations based on individual nail structure and thickness.

Key Market Drivers

  • Aging Population: Elderly individuals are more prone to fungal infections due to weaker immunity and slower nail growth, contributing to a growing patient base.
  • Rising Diabetes Prevalence: Diabetes significantly increases susceptibility to fungal infections, particularly in the feet, where onychomycosis often occurs.
  • Public Spaces and Lifestyle Changes: Increased usage of communal facilities like gyms, pools, and salons heightens exposure to environments conducive to fungal infections.
  • Global Travel and Hygiene Factors: Travel spreads infections regionally, while poor foot hygiene and nail trauma further elevate the risk.
  • Sports and Physical Activity: Active individuals, especially those participating in fitness and outdoor activities, are more susceptible to contracting onychomycosis.
  • Improved Awareness and Diagnostics: Better public awareness and access to diagnostic facilities are prompting earlier treatment, expanding the patient pool.

Market Challenges

  • Limited Treatment Efficacy: Topical treatments often struggle to penetrate the nail bed effectively, and systemic treatments face issues with reaching therapeutic concentrations due to limited blood supply in nails.
  • Prolonged Treatment Duration: Long therapies can result in non-compliance, leading to incomplete cures or recurrence, thereby impacting treatment success rates.

Business Opportunity

The development of novel antifungal drugs is paving the way for faster, more effective, and safer treatment options. Emerging therapies are targeting specific fungal mechanisms, enabling better outcomes and reduced resistance. Combination therapies and advanced delivery systems are further contributing to improved patient satisfaction and market growth.

Shorter treatment durations and better safety profiles are making therapies more attractive to patients, while strategic collaborations between pharmaceutical companies and biotech firms are accelerating research and innovation. Personalized medicine is also on the rise, allowing treatments to be tailored to individual patient needs for optimal results.

Regional Analysis

  • North America: The region continues to lead the market, largely due to a high diabetic population and a strong healthcare infrastructure. Diabetic patients are more vulnerable to fungal infections, increasing demand for effective treatments.
  • Asia Pacific: Rapid population growth, particularly in China and India, combined with an expanding aging population, is driving the region’s market attractiveness. Diverse demographics call for a wide range of treatment options suited to varying patient profiles.
  • Europe and Other Regions: Western European countries with established healthcare systems contribute significantly, while hot and humid climates in Southeast Asia also foster a high prevalence of fungal infections, propelling demand.

Competitive Analysis

Several pharmaceutical giants are actively contributing to market growth.
  • Johnson & Johnson: Engaged in antifungal R&D, with potential repurposing of existing drugs and strategic academic collaborations.
  • Pfizer Inc.: Exploring new applications for assets like crisaborole and leveraging its global distribution network.
  • Lupin: Launched a cost-effective generic version of Tavaborole in the U.S., enhancing access and market penetration.
  • Alembic Pharmaceuticals: Through its joint venture Aleor Dermaceuticals, received tentative USFDA approval for Efinaconazole Topical Solution, offering a competitive alternative to branded products.

Market Segmentation

By Treatment Type:

  • Drugs
  • Oral (Rx, OTC)
  • Topical (Rx, OTC)
  • Lasers
  • CO2 Ablative Lasers
  • Nd: YAG Lasers
  • Dual-wavelength Near-Infrared Lasers
  • Photodynamic Therapy

By Disease Indication:

  • Distal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Proximal Subungual Onychomycosis
  • Candidal Onychomycosis
  • Total Dystrophic Onychomycosis

By Age Group:

  • 0 to 18 Years
  • 18 to 39 Years
  • 40 to 64 Years
  • 65 Years & Above

By Distribution Channel:

  • Institutional Sales
  • Hospitals
  • Dermatology Clinics
  • Retail Sales
  • Retail Pharmacies
  • Drug Stores
  • Mail-Order Pharmacies & Online Sales

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Onychomycosis Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Onychomycosis Treatment Market Outlook, 2019 - 2032
3.1. Global Onychomycosis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2019 - 2032
3.1.1. Key Highlights
3.1.1.1. Drugs
3.1.1.2. Oral
3.1.1.3. Rx
3.1.1.3.1. OTC
3.1.1.3.2. Topical
3.1.1.3.3. Rx
3.1.1.3.4. OTC
3.1.1.4. Lasers
3.1.1.4.1. C02 Ablative Lasers
3.1.1.4.2. Nd: YAG Lasers
3.1.1.4.3. Dual-wavelength near-infrared Lasers
3.1.1.5. Photodynamic Therapy
3.2. Global Onychomycosis Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2019 - 2032
3.2.1. Key Highlights
3.2.1.1. Distal Subungual Onychomycosis
3.2.1.2. White Superficial Onychomycosis
3.2.1.3. Proximal Subungual Onychomycosis
3.2.1.4. Candidal Onychomycosis
3.2.1.5. Total Dystrophic Onychomycosis
3.3. Global Onychomycosis Treatment Market Outlook, by Age Group, Value (US$ Bn), 2019 - 2032
3.3.1. Key Highlights
3.3.1.1. 0 to 18 Years
3.3.1.2. 18 to 39 Years
3.3.1.3. 40 to 64 Years
3.3.1.4. 65 Years & Above
3.4. Global Onychomycosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
3.4.1. Key Highlights
3.4.1.1. Institutional Sales
3.4.1.2. Hospitals
3.4.1.3. Dermatology Clinics
3.4.1.4. Retail Sales
3.4.1.5. Retail Pharmacies
3.4.1.6. Drug Stores
3.4.1.7. Mail Order Pharmacies & Online Sales
3.5. Global Onychomycosis Treatment Market Outlook, by Region, Value (US$ Bn), 2019 - 2032
3.5.1. Key Highlights
3.5.1.1. North America
3.5.1.2. Europe
3.5.1.3. Asia Pacific
3.5.1.4. Latin America
3.5.1.5. Middle East & Africa
4. North America Onychomycosis Treatment Market Outlook, 2019 - 2032
4.1. North America Onychomycosis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2019 - 2032
4.1.1. Key Highlights
4.1.1.1. Drugs
4.1.1.2. Oral
4.1.1.3. Rx
4.1.1.3.1. OTC
4.1.1.3.2. Topical
4.1.1.3.3. Rx
4.1.1.3.4. OTC
4.1.1.4. Lasers
4.1.1.4.1. C02 Ablative Lasers
4.1.1.4.2. Nd: YAG Lasers
4.1.1.4.3. Dual-wavelength near-infrared Lasers
4.1.1.5. Photodynamic Therapy
4.2. North America Onychomycosis Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2019 - 2032
4.2.1. Key Highlights
4.2.1.1. Distal Subungual Onychomycosis
4.2.1.2. White Superficial Onychomycosis
4.2.1.3. Proximal Subungual Onychomycosis
4.2.1.4. Candidal Onychomycosis
4.2.1.5. Total Dystrophic Onychomycosis
4.3. North America Onychomycosis Treatment Market Outlook, by Age Group, Value (US$ Bn), 2019 - 2032
4.3.1. Key Highlights
4.3.1.1. 0 to 18 Years
4.3.1.2. 18 to 39 Years
4.3.1.3. 40 to 64 Years
4.3.1.4. 65 Years & Above
4.4. North America Onychomycosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
4.4.1. Key Highlights
4.4.1.1. Institutional Sales
4.4.1.2. Hospitals
4.4.1.3. Dermatology Clinics
4.4.1.4. Retail Sales
4.4.1.5. Retail Pharmacies
4.4.1.6. Drug Stores
4.4.1.7. Mail Order Pharmacies & Online Sales
4.5. North America Onychomycosis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
4.5.1. Key Highlights
4.5.1.1. U.S. Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
4.5.1.2. U.S. Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
4.5.1.3. U.S. Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
4.5.1.4. U.S. Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
4.5.1.5. Canada Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
4.5.1.6. Canada Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
4.5.1.7. Canada Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
4.5.1.8. Canada Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
4.5.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Onychomycosis Treatment Market Outlook, 2019 - 2032
5.1. Europe Onychomycosis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2019 - 2032
5.1.1. Key Highlights
5.1.1.1. Drugs
5.1.1.2. Oral
5.1.1.3. Rx
5.1.1.3.1. OTC
5.1.1.3.2. Topical
5.1.1.3.3. Rx
5.1.1.3.4. OTC
5.1.1.4. Lasers
5.1.1.4.1. C02 Ablative Lasers
5.1.1.4.2. Nd: YAG Lasers
5.1.1.4.3. Dual-wavelength near-infrared Lasers
5.1.1.5. Photodynamic Therapy
5.2. Europe Onychomycosis Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2019 - 2032
5.2.1. Key Highlights
5.2.1.1. Distal Subungual Onychomycosis
5.2.1.2. White Superficial Onychomycosis
5.2.1.3. Proximal Subungual Onychomycosis
5.2.1.4. Candidal Onychomycosis
5.2.1.5. Total Dystrophic Onychomycosis
5.3. Europe Onychomycosis Treatment Market Outlook, by Age Group, Value (US$ Bn), 2019 - 2032
5.3.1. Key Highlights
5.3.1.1. 0 to 18 Years
5.3.1.2. 18 to 39 Years
5.3.1.3. 40 to 64 Years
5.3.1.4. 65 Years & Above
5.4. Europe Onychomycosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
5.4.1. Key Highlights
5.4.1.1. Institutional Sales
5.4.1.2. Hospitals
5.4.1.3. Dermatology Clinics
5.4.1.4. Retail Sales
5.4.1.5. Retail Pharmacies
5.4.1.6. Drug Stores
5.4.1.7. Mail Order Pharmacies & Online Sales
5.5. Europe Onychomycosis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
5.5.1. Key Highlights
5.5.1.1. Germany Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
5.5.1.2. Germany Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
5.5.1.3. Germany Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
5.5.1.4. Germany Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
5.5.1.5. U.K. Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
5.5.1.6. U.K. Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
5.5.1.7. U.K. Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
5.5.1.8. U.K. Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
5.5.1.9. France Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
5.5.1.10. France Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
5.5.1.11. France Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
5.5.1.12. France Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
5.5.1.13. Italy Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
5.5.1.14. Italy Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
5.5.1.15. Italy Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
5.5.1.16. Italy Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
5.5.1.17. Turkey Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
5.5.1.18. Turkey Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
5.5.1.19. Turkey Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
5.5.1.20. Turkey Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
5.5.1.21. Russia Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
5.5.1.22. Russia Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
5.5.1.23. Russia Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
5.5.1.24. Russia Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
5.5.1.25. Rest of Europe Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
5.5.1.26. Rest of Europe Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
5.5.1.27. Rest of Europe Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
5.5.1.28. Rest of Europe Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
5.5.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Onychomycosis Treatment Market Outlook, 2019 - 2032
6.1. Asia Pacific Onychomycosis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2019 - 2032
6.1.1. Key Highlights
6.1.1.1. Drugs
6.1.1.2. Oral
6.1.1.3. Rx
6.1.1.3.1. OTC
6.1.1.3.2. Topical
6.1.1.3.3. Rx
6.1.1.3.4. OTC
6.1.1.4. Lasers
6.1.1.4.1. C02 Ablative Lasers
6.1.1.4.2. Nd: YAG Lasers
6.1.1.4.3. Dual-wavelength near-infrared Lasers
6.1.1.5. Photodynamic Therapy
6.2. Asia Pacific Onychomycosis Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2019 - 2032
6.2.1. Key Highlights
6.2.1.1. Distal Subungual Onychomycosis
6.2.1.2. White Superficial Onychomycosis
6.2.1.3. Proximal Subungual Onychomycosis
6.2.1.4. Candidal Onychomycosis
6.2.1.5. Total Dystrophic Onychomycosis
6.3. Asia Pacific Onychomycosis Treatment Market Outlook, by Age Group, Value (US$ Bn), 2019 - 2032
6.3.1. Key Highlights
6.3.1.1. 0 to 18 Years
6.3.1.2. 18 to 39 Years
6.3.1.3. 40 to 64 Years
6.3.1.4. 65 Years & Above
6.4. Asia Pacific Onychomycosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
6.4.1. Key Highlights
6.4.1.1. Institutional Sales
6.4.1.2. Hospitals
6.4.1.3. Dermatology Clinics
6.4.1.4. Retail Sales
6.4.1.5. Retail Pharmacies
6.4.1.6. Drug Stores
6.4.1.7. Mail Order Pharmacies & Online Sales
6.5. Asia Pacific Onychomycosis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
6.5.1. Key Highlights
6.5.1.1. China Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
6.5.1.2. China Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
6.5.1.3. China Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
6.5.1.4. China Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
6.5.1.5. Japan Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
6.5.1.6. Japan Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
6.5.1.7. Japan Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
6.5.1.8. Japan Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
6.5.1.9. South Korea Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
6.5.1.10. South Korea Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
6.5.1.11. South Korea Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
6.5.1.12. South Korea Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
6.5.1.13. India Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
6.5.1.14. India Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
6.5.1.15. India Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
6.5.1.16. India Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
6.5.1.17. Southeast Asia Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
6.5.1.18. Southeast Asia Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
6.5.1.19. Southeast Asia Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
6.5.1.20. Southeast Asia Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
6.5.1.21. Rest of Asia Pacific Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
6.5.1.22. Rest of Asia Pacific Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
6.5.1.23. Rest of Asia Pacific Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
6.5.1.24. Rest of Asia Pacific Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
6.5.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Onychomycosis Treatment Market Outlook, 2019 - 2032
7.1. Latin America Onychomycosis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2019 - 2032
7.1.1. Key Highlights
7.1.1.1. Drugs
7.1.1.2. Oral
7.1.1.3. Rx
7.1.1.3.1. OTC
7.1.1.3.2. Topical
7.1.1.3.3. Rx
7.1.1.3.4. OTC
7.1.1.4. Lasers
7.1.1.4.1. C02 Ablative Lasers
7.1.1.4.2. Nd: YAG Lasers
7.1.1.4.3. Dual-wavelength near-infrared Lasers
7.1.1.5. Photodynamic Therapy
7.2. Latin America Onychomycosis Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2019 - 2032
7.2.1. Key Highlights
7.2.1.1. Distal Subungual Onychomycosis
7.2.1.2. White Superficial Onychomycosis
7.2.1.3. Proximal Subungual Onychomycosis
7.2.1.4. Candidal Onychomycosis
7.2.1.5. Total Dystrophic Onychomycosis
7.3. Latin America Onychomycosis Treatment Market Outlook, by Age Group, Value (US$ Bn), 2019 - 2032
7.3.1. Key Highlights
7.3.1.1. 0 to 18 Years
7.3.1.2. 18 to 39 Years
7.3.1.3. 40 to 64 Years
7.3.1.4. 65 Years & Above
7.4. Latin America Onychomycosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
7.4.1. Key Highlights
7.4.1.1. Institutional Sales
7.4.1.2. Hospitals
7.4.1.3. Dermatology Clinics
7.4.1.4. Retail Sales
7.4.1.5. Retail Pharmacies
7.4.1.6. Drug Stores
7.4.1.7. Mail Order Pharmacies & Online Sales
7.5. Latin America Onychomycosis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
7.5.1. Key Highlights
7.5.1.1. Brazil Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
7.5.1.2. Brazil Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
7.5.1.3. Brazil Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
7.5.1.4. Brazil Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
7.5.1.5. Mexico Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
7.5.1.6. Mexico Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
7.5.1.7. Mexico Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
7.5.1.8. Mexico Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
7.5.1.9. Argentina Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
7.5.1.10. Argentina Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
7.5.1.11. Argentina Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
7.5.1.12. Argentina Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
7.5.1.13. Rest of Latin America Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
7.5.1.14. Rest of Latin America Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
7.5.1.15. Rest of Latin America Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
7.5.1.16. Rest of Latin America Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
7.5.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Onychomycosis Treatment Market Outlook, 2019 - 2032
8.1. Middle East & Africa Onychomycosis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2019 - 2032
8.1.1. Key Highlights
8.1.1.1. Drugs
8.1.1.2. Oral
8.1.1.3. Rx
8.1.1.3.1. OTC
8.1.1.3.2. Topical
8.1.1.3.3. Rx
8.1.1.3.4. OTC
8.1.1.4. Lasers
8.1.1.4.1. C02 Ablative Lasers
8.1.1.4.2. Nd: YAG Lasers
8.1.1.4.3. Dual-wavelength near-infrared Lasers
8.1.1.5. Photodynamic Therapy
8.2. Middle East & Africa Onychomycosis Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2019 - 2032
8.2.1. Key Highlights
8.2.1.1. Distal Subungual Onychomycosis
8.2.1.2. White Superficial Onychomycosis
8.2.1.3. Proximal Subungual Onychomycosis
8.2.1.4. Candidal Onychomycosis
8.2.1.5. Total Dystrophic Onychomycosis
8.3. Middle East & Africa Onychomycosis Treatment Market Outlook, by Age Group, Value (US$ Bn), 2019 - 2032
8.3.1. Key Highlights
8.3.1.1. 0 to 18 Years
8.3.1.2. 18 to 39 Years
8.3.1.3. 40 to 64 Years
8.3.1.4. 65 Years & Above
8.4. Middle East & Africa Onychomycosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
8.4.1. Key Highlights
8.4.1.1. Institutional Sales
8.4.1.2. Hospitals
8.4.1.3. Dermatology Clinics
8.4.1.4. Retail Sales
8.4.1.5. Retail Pharmacies
8.4.1.6. Drug Stores
8.4.1.7. Mail Order Pharmacies & Online Sales
8.5. Middle East & Africa Onychomycosis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
8.5.1. Key Highlights
8.5.1.1. GCC Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
8.5.1.2. GCC Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
8.5.1.3. GCC Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
8.5.1.4. GCC Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
8.5.1.5. South Africa Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
8.5.1.6. South Africa Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
8.5.1.7. South Africa Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
8.5.1.8. South Africa Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
8.5.1.9. Egypt Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
8.5.1.10. Egypt Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
8.5.1.11. Egypt Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
8.5.1.12. Egypt Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
8.5.1.13. Nigeria Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
8.5.1.14. Nigeria Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
8.5.1.15. Nigeria Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
8.5.1.16. Nigeria Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
8.5.1.17. Rest of Middle East & Africa Onychomycosis Treatment Market by Treatment Type, Value (US$ Bn), 2019 - 2032
8.5.1.18. Rest of Middle East & Africa Onychomycosis Treatment Market by Disease Indication, Value (US$ Bn), 2019 - 2032
8.5.1.19. Rest of Middle East & Africa Onychomycosis Treatment Market by Age Group, Value (US$ Bn), 2019 - 2032
8.5.1.20. Rest of Middle East & Africa Onychomycosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
8.5.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By Age Group vs By Disease Indication Heatmap
9.2. Company Market Share Analysis, 2025
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Medtronic plc
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Teva Pharmaceutical Industries Ltd.
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Sanofi S.A.
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Medimetriks Pharmaceuticals, Inc.
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Galderma
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Johnson & Johnson
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Novartis AG
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Moberg Pharma AB
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. Cardinal Health, Inc.
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. Pfizer Inc.
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
9.4.11. Almirall, S.A.
9.4.11.1. Company Overview
9.4.11.2. Product Portfolio
9.4.11.3. Financial Overview
9.4.11.4. Business Strategies and Development
9.4.12. Bayer AG
9.4.12.1. Company Overview
9.4.12.2. Product Portfolio
9.4.12.3. Financial Overview
9.4.12.4. Business Strategies and Development
9.4.13. Viatris Inc.
9.4.13.1. Company Overview
9.4.13.2. Product Portfolio
9.4.13.3. Financial Overview
9.4.13.4. Business Strategies and Development
9.4.14. GlaxoSmithKline plc
9.4.14.1. Company Overview
9.4.14.2. Product Portfolio
9.4.14.3. Financial Overview
9.4.14.4. Business Strategies and Development
9.4.15. Cipla Ltd.
9.4.15.1. Company Overview
9.4.15.2. Product Portfolio
9.4.15.3. Financial Overview
9.4.15.4. Business Strategies and Development
9.4.16. Dr. Reddy’s Laboratories Ltd
9.4.16.1. Company Overview
9.4.16.2. Product Portfolio
9.4.16.3. Financial Overview
9.4.16.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Medimetriks Pharmaceuticals, Inc.
  • Galderma
  • Johnson & Johnson
  • Novartis AG
  • Moberg Pharma AB
  • Cardinal Health, Inc.
  • Pfizer Inc.
  • Almirall, S.A.
  • Bayer AG
  • Viatris Inc.
  • GlaxoSmithKline plc
  • Cipla Ltd.
  • Dr. Reddy’s Laboratories Ltd

Methodology

Loading
LOADING...

Related Topics

Related Reports

Dermatophytic Onychomycosis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Dermatophytic Onychomycosis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 336 Pages
  • Global
Onychomycosis Treatment Market Report by Disease Type, Treatment Type, Drug Class, Distribution Channel, and Region 2024-2032 - Product Image

Onychomycosis Treatment Market Report by Disease Type, Treatment Type, Drug Class, Distribution Channel, and Region 2024-2032

  • Report
  • 143 Pages
  • Global
From
Onychomycosis Market Report and Forecast 2024-2032 - Product Image

Onychomycosis Market Report and Forecast 2024-2032

  • Report
  • 160 Pages
  • Global
From
Onychomycosis - Epidemiology Forecast - 2032 - Product Image

Onychomycosis - Epidemiology Forecast - 2032

  • Report
  • 87 Pages
  • Global
From
Onychomycosis - Market Insight, Epidemiology And Market Forecast - 2032 - Product Image

Onychomycosis - Market Insight, Epidemiology And Market Forecast - 2032

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.